AI‑Enabled MRD

The acquisition is aimed at bolstering TEM’s minimal residual disease (MRD) testing capabilities. TEM notes that its MRD offering has seen a 38 % quarter‑over‑quarter growth and that embedding additional AI‑enabled ordering tools and hospital connectivity will further enhance the platform. Personalis’ NeXT Personal assay has secured Medicare coverage in three indications and is expanding reimbursement across additional indications. TEM’s CEO Eric Lefkofsky stated that integrating Personalis’ technology with TEM’s commercial infrastructure could elevate the company to adjusted EBITDA and free‑cash‑flow positive status by 2027.